$16.02-3.1%Nov 13 close
Figures through September 30, 2026, from the 10-Q filed October 28, 2026
Company outlook: revenue of about $209M for Fiscal Q3 2026 — up 11.3% on a year earlier
Just reported
From Neogenomics Inc.'s results release of October 28, 2026; its quarterly report has since been filed.
Actual
$209.3M
+11% y/y
+3.8% q/q
Guided
$209M
midpoint
Actual
-$7.9M
Guided
—
No guide given
Set against the company's own guidance and the same quarter a year earlier, not analysts' estimates, which we do not hold. Adjusted figures are the company's own non-GAAP measures, as stated in the release.
| Measure | 3 months toSep 30, 2026 | 3 months toSep 30, 2025 | Change |
|---|---|---|---|
| Total Revenue | $209.3M | $187.8M | +11.43% |
| Profit | -$7.5M | -$27.1M | +72.18% |
| Free Cash Flow | -$20.7M | $570K | -3,724.21% |
These are single quarters, not a trailing year — the figures elsewhere on this site cover twelve months and will be much larger. A seasonal business swings a long way between the two: ServiceNow earns $2.0B of free cash flow in its December quarter and $0.5B in its June one.
Compared against the same quarter a year earlier, not against an analyst forecast. A “beat” or “miss” needs a consensus estimate, which is licensed data we do not carry — and getting it wrong is worse than leaving it out.
Neogenomics Inc. has no earnings call transcript available.
“Our third-quarter results reinforce that we have the right strategy in place and the right team to execute against it,”
Quoted verbatim from the release, and shown only when the filing attributes it to a named person.
Releases land before the open or after the close, so the window runs from the close before the report day to the close of the session after it — the reaction is inside it either way.
NeoGenomics, Inc. is a premier cancer diagnostics company specializing in cancer genetics testing and information services. We offer one of the most comprehensive oncology-focused testing menus across the cancer continuum, providing oncologists, pathologists, hospital systems, academic medical centers, and pharmaceutical firms with innovative diagnostic and predictive testing to deliver timely, actionable insights that guide personalized care decisions. Headquartered in Fort Myers, FL, NeoGenomics operates a network of CAP-accredited and CLIA-certified laboratories for full-service sample processing and analysis services throughout the US and a CAP-accredited full-service sample-processing laboratory in Cambridge, England. We routinely post information that may be important to investors on our website at https://www.neogenomics.com. Information on, or accessible through, our website is not incorporated by reference into, and is not a part of, this release or any other report or document that we may file with the Securities and Exchange Commission (“SEC”).
The company’s own description, as it appears at the foot of the release.
The quote and the company description come from Neogenomics Inc.’s Item 2.02 8-K filed October 28, 2026; the table is built from its quarterly reports. Read the release on EDGAR Share prices are split- and dividend-adjusted.